Effects of the COVID-19 pandemic on a cohort of patients with vein occlusion()

BACKGROUND AND OBJECTIVES: A new coronavirus disease in humans, COVID-19, caused by SARS-CoV-2, emerged in December 2019. It has been associated with the development of thrombotic phenomena. Retinal vein occlusion (RVO) is mainly a consequence of vascular risk factors (VRF). This study aimed to anal...

Descripción completa

Detalles Bibliográficos
Autores principales: García Palacios, J.D., Puente Ruiz, N., Napal Lecumberri, J.J., Hernández Hernández, J.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). 2021
Materias:
Brief Original
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450061/
https://www.ncbi.nlm.nih.gov/pubmed/34565709
http://dx.doi.org/10.1016/j.rceng.2021.06.003
Descripción
Sumario:BACKGROUND AND OBJECTIVES: A new coronavirus disease in humans, COVID-19, caused by SARS-CoV-2, emerged in December 2019. It has been associated with the development of thrombotic phenomena. Retinal vein occlusion (RVO) is mainly a consequence of vascular risk factors (VRF). This study aimed to analyze cases of COVID-19 in a cohort of patients with RVO (Valdecilla cohort). PATIENTS AND METHODS: Between December 2008 and December 2020, 429 patients with RVO were attended to in our clinic. Ten patients had COVID-19, one of which did not have VRF or thrombophilia. The remaining nine patients had RVO prior to the infection and VRF, six had carotid atherosclerosis, and four had antiphospholipid syndrome. The infection did not cause thrombotic phenomena in any of them. CONCLUSIONS: RVO is a rare manifestation of COVID-19. In our cohort of patients with RVO, COVID-19 disease did not lead to thrombotic events.

Ejemplares similares